Stevanato Group (NYSE:STVN) Stock Gets Price Target Trim from UBS Group

Stevanato Group (NYSE:STVN) had its target price lowered by UBS Group from $23.00 to $16.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other equities analysts have also weighed in on the company. Deutsche Bank Aktiengesellschaft started coverage on Stevanato Group in a research note on Wednesday, October 7th. They issued a “hold” rating for the company. Citigroup lowered their price target on Stevanato Group from $26.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday. William Blair lowered Stevanato Group from an “outperform” rating to a “market perform” rating in a report on Wednesday. Finally, Weiss Ratings upgraded Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, August 27th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stevanato Group currently has an average rating of “Moderate Buy”.

Stevanato Group Stock Performance

NYSE:STVN traded up €0.25 during mid-day trading on Wednesday, hitting €13.46. The company’s stock had a trading volume of 1,365,000 shares, compared to its average volume of 558,109. The stock has a market cap of $4.08 billion, a price-to-earnings ratio of 23.20, a PEG ratio of 1.62 and a beta of 0.80. The business’s fifty day moving average is €19.80 and its two-hundred day moving average is €18.01. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.61 and a quick ratio of 1.08. Stevanato Group has a 1 year low of €12.05 and a 1 year high of €25.45.

Stevanato Group (NYSE:STVN) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported €0.16 EPS for the quarter, missing analysts’ consensus estimates of €0.17 by (€0.01). Stevanato Group had a return on equity of 10.43% and a net margin of 10.99%. The firm had revenue of €326.06 million for the quarter. Analysts anticipate that Stevanato Group will post 0.67 EPS for the current fiscal year.

Insider Buying and Selling at Stevanato Group

In other news, insider Mauro Stocchi sold 13,649 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The stock was sold at an average price of €21.50, for a total value of €293,453.50. Following the transaction, the insider owned 400,000 shares in the company, valued at €8,600,000. This trade represents a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.70% of the stock is currently owned by company insiders.

Institutional Trading of Stevanato Group

Several large investors have recently made changes to their positions in STVN. Fifth Third Bancorp increased its position in shares of Stevanato Group by 22.6% during the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after purchasing an additional 773 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Stevanato Group in the 2nd quarter valued at $59,000. State of Wyoming acquired a new stake in Stevanato Group during the 3rd quarter worth $75,000. Diversify Wealth Management LLC boosted its stake in Stevanato Group by 23.9% during the 1st quarter. Diversify Wealth Management LLC now owns 18,353 shares of the company’s stock worth $252,000 after purchasing an additional 3,543 shares during the last quarter. Finally, First Bank & Trust boosted its stake in Stevanato Group by 3.4% during the 2nd quarter. First Bank & Trust now owns 18,417 shares of the company’s stock worth $333,000 after purchasing an additional 603 shares during the last quarter.

About Stevanato Group

Stevanato Group S.p.A. is an Italy-based provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and healthcare industries. Founded in 1949, the company has developed from a glass-packaging manufacturer into an integrated supplier serving customers throughout the global pharmaceutical supply chain.

The company manufactures primary packaging products, including glass vials, syringes, cartridges and ampoules, as well as components and systems used to contain and administer injectable medicines.